Stevanato Group (NYSE:STVN) opened 2026 with Q1 revenue of €273.6 million and basic EPS of €0.10, alongside trailing 12 month revenue of about €1.2 billion and EPS of €0.52 that frame the latest quarter against a fuller earnings backdrop. Over recent periods, revenue has ranged from €256.6 million in Q1 2025 to €346.5 million in Q4 2025, while basic EPS has moved between €0.10 and €0.17 across those quarters, giving investors a clear view of how the top and bottom lines are tracking into the current year. With trailing net profit margins at 11.7% and recent earnings momentum in focus, the story now centers on how durable those margins look as growth drivers play through.

See our full analysis for Stevanato Group.

With the headline numbers in place, the next step is to see how this earnings profile lines up with the widely held narratives around Stevanato Group's growth trajectory, risk balance, and long term profitability story.

12.6% Earnings Growth Outpaces 8.1% Revenue Trend

• Over the last 12 months, earnings grew 12.6% while revenue growth sat at 8.1%, with net profit of about €141.3 million on €1.2b of revenue.
• Consensus narrative points to demand for higher value drug containment and delivery solutions as a key earnings driver. However, the 8.1% revenue growth rate sitting below the 11.4% US market benchmark highlights that:
  • Stronger earnings growth than revenue growth relies heavily on improving margins, with net margin at 11.7% versus 11.2% a year earlier.
  • Any slowdown in that margin uplift would mean earnings growth falls closer to the 8.1% revenue pace, which would be less supportive of the more optimistic growth story.

Margins At 11.7% Test The Bullish Thesis

• Trailing net profit margin is 11.7%, only modestly above 11.2% a year earlier, alongside trailing EPS of €0.52 on €1.2b of revenue.
• Bullish investors expect margins to move meaningfully higher over time. Yet current figures offer a mixed read on that view:
  • Recent acceleration in earnings, with 12.6% earnings growth versus a 1.8% five year compound rate, supports the idea that higher value products and capacity investments are starting to show through in profits.
  • However, with the latest reported margin still close to the prior 11.2% level, the data so far only partially backs the more aggressive bullish assumption of much bigger margin gains in later years.

On the back of this early margin improvement, it is worth seeing how bullish and bearish investors each frame the next few years for Stevanato Group 🐂 Stevanato Group Bull Case

P/E Of 29.7x And €18.03 Share Price Versus Targets

• The stock trades at about €18.03 with a trailing P/E of 29.7x, compared with an analyst consensus target of €24.81 and a DCF fair value of €32.72, while the P/E sits below the Global Life Sciences average of 37.1x and well below the cited peer average of 58.7x.
• Bears highlight that slower revenue growth could limit how far the valuation can stretch, and the current figures give you a clear sense of that trade off:
  • Forecast revenue growth of 8.1% per year is below the 11.4% US market reference, which fits the cautious view that top line expansion may not fully support higher valuation multiples.
  • At the same time, earnings growth of 12.6% over the last year and an 11.7% net margin provide some counterweight to that concern, as they point to improving profitability even with more moderate revenue growth.

If you are weighing whether the current P/E leaves enough room for the cautious case, it helps to see how skeptics frame the long term risks alongside these valuation markers 🐻 Stevanato Group Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Stevanato Group on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Seeing both optimistic and cautious angles in this earnings story, it makes sense to review the numbers yourself and decide how convincing the reward case really is. To understand exactly what investors are feeling positive about, take a closer look at the 3 key rewards.

See What Else Is Out There

Stevanato Group combines a 29.7x P/E with revenue growth of 8.1% that trails the 11.4% US market benchmark, which tempers the bullish thesis.

If you are uneasy about paying up for slower top line momentum, it makes sense to compare this stock against companies flagged in the 51 high quality undervalued stocks so you can quickly see where growth, price and quality may line up more compellingly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.